150 related articles for article (PubMed ID: 38065340)
21. Targeting MSS colorectal cancer with immunotherapy: are we turning the corner?
Wang C; Fakih M
Expert Opin Biol Ther; 2021 Oct; 21(10):1347-1357. PubMed ID: 34030532
[TBL] [Abstract][Full Text] [Related]
22. Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment.
Yu G; Wu Y; Wang W; Xu J; Lv X; Cao X; Wan T
Cell Mol Immunol; 2019 Apr; 16(4):401-409. PubMed ID: 29622799
[TBL] [Abstract][Full Text] [Related]
23. A new strategy for immunotherapy of microsatellite-stable (MSS)-type advanced colorectal cancer: Multi-pathway combination therapy with PD-1/PD-L1 inhibitors.
Cai L; Chen A; Tang D
Immunology; 2024 Mar; ():. PubMed ID: 38517066
[TBL] [Abstract][Full Text] [Related]
24. Chr20q Amplification Defines a Distinct Molecular Subtype of Microsatellite Stable Colorectal Cancer.
Zhang B; Yao K; Zhou E; Zhang L; Cheng C
Cancer Res; 2021 Apr; 81(8):1977-1987. PubMed ID: 33619118
[TBL] [Abstract][Full Text] [Related]
25. Low molecular weight heparin synergistically enhances the efficacy of adoptive and anti-PD-1-based immunotherapy by increasing lymphocyte infiltration in colorectal cancer.
Quan Y; He J; Zou Q; Zhang L; Sun Q; Huang H; Li W; Xie K; Wei F
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37597850
[TBL] [Abstract][Full Text] [Related]
26. The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer: A Systematic Review.
Guven DC; Kavgaci G; Erul E; Syed MP; Magge T; Saeed A; Yalcin S; Sahin IH
Oncologist; 2024 May; 29(5):e580-e600. PubMed ID: 38309719
[TBL] [Abstract][Full Text] [Related]
27. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer.
Lin A; Zhang J; Luo P
Front Immunol; 2020; 11():2039. PubMed ID: 32903444
[TBL] [Abstract][Full Text] [Related]
28. The role of immune checkpoint inhibitors for patients with advanced stage microsatellite stable colorectal cancer and high tumor mutation burden: quantity or quality?
Vegivinti CTR; Gonzales Gomez C; Syed M; Ferrell M; Cheng S; Singhi A; Saeed A; Sahin IH
Expert Opin Biol Ther; 2023; 23(7):595-601. PubMed ID: 37318031
[TBL] [Abstract][Full Text] [Related]
29. Molecular and Radiological Features of Microsatellite Stable Colorectal Cancer Cases With Dramatic Responses to Immunotherapy.
Keenan BP; VAN Loon K; Khilnani AD; Fidelman N; Behr SC; Atreya CE; Oh DY
Anticancer Res; 2021 Jun; 41(6):2985-2992. PubMed ID: 34083289
[TBL] [Abstract][Full Text] [Related]
30. Clinical Application of Adaptive Immune Therapy in MSS Colorectal Cancer Patients.
Wang D; Zhang H; Xiang T; Wang G
Front Immunol; 2021; 12():762341. PubMed ID: 34721435
[TBL] [Abstract][Full Text] [Related]
31. Durable complete response to pembrolizumab in microsatellite stable colorectal cancer.
Gomar M; Najafi M; Aghili M; Cozzi S; Jahanbakhshi A
Daru; 2021 Dec; 29(2):501-506. PubMed ID: 34254265
[TBL] [Abstract][Full Text] [Related]
32. Shaping immune landscape of colorectal cancer by cholesterol metabolites.
Bai Y; Li T; Wang Q; You W; Yang H; Xu X; Li Z; Zhang Y; Yan C; Yang L; Qiu J; Liu Y; Chen S; Wang D; Huang B; Liu K; Song BL; Wang Z; Li K; Liu X; Wang G; Yang W; Chen J; Hao P; Zhang Z; Wang Z; Zhu ZJ; Xu C
EMBO Mol Med; 2024 Feb; 16(2):334-360. PubMed ID: 38177537
[TBL] [Abstract][Full Text] [Related]
33. Targeting euchromatic histone lysine methyltransferases sensitizes colorectal cancer to histone deacetylase inhibitors.
Bamberg LV; Heigwer F; Wandmacher AM; Singh A; Betge J; Rindtorff N; Werner J; Josten J; Skabkina OV; Hinsenkamp I; Erdmann G; Röcken C; Ebert MP; Burgermeister E; Zhan T; Boutros M
Int J Cancer; 2022 Nov; 151(9):1586-1601. PubMed ID: 35666536
[TBL] [Abstract][Full Text] [Related]
34. PPARγ induces PD-L1 expression in MSS+ colorectal cancer cells.
Gutting T; Hauber V; Pahl J; Klapproth K; Wu W; Dobrota I; Herweck F; Reichling J; Helm L; Schroeder T; Li B; Weidner P; Zhan T; Eckardt M; Betge J; Belle S; Sticht C; Gaiser T; Boutros M; Ebert MPA; Cerwenka A; Burgermeister E
Oncoimmunology; 2021 May; 10(1):1906500. PubMed ID: 34026331
[TBL] [Abstract][Full Text] [Related]
35. Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters.
Pakish JB; Zhang Q; Chen Z; Liang H; Chisholm GB; Yuan Y; Mok SC; Broaddus RR; Lu KH; Yates MS
Clin Cancer Res; 2017 Aug; 23(15):4473-4481. PubMed ID: 28264871
[No Abstract] [Full Text] [Related]
36. Relationship between microsatellite status and immune microenvironment of colorectal cancer and its application to diagnosis and treatment.
Bai J; Chen H; Bai X
J Clin Lab Anal; 2021 Jun; 35(6):e23810. PubMed ID: 33938589
[TBL] [Abstract][Full Text] [Related]
37. T Cells in Colorectal Cancer: Unravelling the Function of Different T Cell Subsets in the Tumor Microenvironment.
Zheng Z; Wieder T; Mauerer B; Schäfer L; Kesselring R; Braumüller H
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511431
[TBL] [Abstract][Full Text] [Related]
38. Combined Microsatellite Instability and Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) Might Be a More Promising Immune Biomarker in Colorectal Cancer.
Chen MH; Chang SC; Lin PC; Yang SH; Lin CC; Lan YT; Lin HH; Lin CH; Lai JI; Liang WY; Lu ML; Yang MH; Chao Y
Oncologist; 2019 Dec; 24(12):1534-1542. PubMed ID: 31292272
[TBL] [Abstract][Full Text] [Related]
39. Validation of computational determination of microsatellite status using whole exome sequencing data from colorectal cancer patients.
Johansen AFB; Kassentoft CG; Knudsen M; Laursen MB; Madsen AH; Iversen LH; Sunesen KG; Rasmussen MH; Andersen CL
BMC Cancer; 2019 Oct; 19(1):971. PubMed ID: 31638937
[TBL] [Abstract][Full Text] [Related]
40. Potential Mechanism of Immune Evasion Associated with the Master Regulator ASCL2 in Microsatellite Stability in Colorectal Cancer.
Yang Q; Huang G; Li L; Li E; Xu L
J Immunol Res; 2021; 2021():5964752. PubMed ID: 33628843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]